Polymerase chain reaction (PCR) DNA quantitation (PDQ) susceptibility testing rapidly and directly measures nucleoside sensitivity of human immunodeficiency virus type 1 (HIV-1) isolates. PCR is used to quantitate the amount of HIV-1 DNA synthesized after in vitro infection of peripheral blood mononuclear cells. The relative amounts of HIV-1 DNA in cell lysates from cultures maintained at different drug concentrations reflect drug inhibition of virus replication. The results of PDQ susceptibility testing of 2-or 3-day cultures are supported by assays measuring HIV-1 p24 antigen production in supernatants of 7-or 10-day cultures. DNA sequence analyses to identify mutations in the reverse transcriptase gene that cause resistance to 3'-azido-3'-deoxythymidine also support the PDQ results. With the PDQ method, both infectivity titration and susceptibility testing can be performed on supernatants from primary cultures of peripheral blood mononuclear cells. PDQ susceptibility testing should facilitate epidemiologic studies of the clinical significance of drug-resistant HIV-1 isolates.
Human immunodeficiency virus type 1 (HIV-1) isolates resistant to zidovudine (3'-azido-3'-deoxythymidine, AZT) and didanosine (2',3'-dideoxyinosine, ddl) have been reported, but the role of drug-resistant HIV-1 in pathogenesis is not well defined (1) (2) (3) . Rapid, quantitative drug susceptibility testing of all isolates, and not only the minority that replicate in MT-2 cells (1, 4) , is necessary for epidemiologic evaluation of the contribution of resistant HIV-1 to disease progression. To obtain an HIV-1 isolate from virtually every subject, each HIV-1-infected subject's peripheral blood mononuclear cells (PBMCs) must be cocultivated with an uninfected donor's phytohemagglutinin (PHA)-stimulated PBMCs. We have developed a rapid method for drug susceptibility testing that allows the use of the supernatants of such primary cocultures. The polymerase chain reaction (PCR) is used to determine relative amounts of HIV-1 DNA in cultures maintained in different drug concentrations following in vitro infection. The results of this PCR DNA quantitation (PDQ) susceptibility testing are supported by HIV-1 p24 antigenbased susceptibility assays (5) and by DNA sequencing of codons in the HIV-1 reverse transcriptase (RT) gene in which specific mutations cause AZT resistance (2) .
MATERIALS AND METHODS
Cell and Virus Culture. Primary PBMC coculture supernatants were used. These were in excess of those stored for use in virologic assessment of clinical protocols. Primary coculture of HIV-1 was performed with 5 x 106 3-day PHA (10 gg/ml; Difco)-stimulated PBMCs from a single HIV-1-seronegative blood donor and 10 x 106 PBMCs (or 1 ml of plasma) from an HIV-1-infected subject (5) . Virus stocks were generated from passage of primary coculture supernatants on PHA-stimulated PBMCs (5) .
Prior to each PDQ experiment, virus inocula were first filtered (Millex HV, 0.45 ,um, Millipore) and then treated with RQ1 RNase-free DNase (Promega) in 1 mM MgCl2 (4 units of DNase per ml of culture supernatant) for 20 min at room temperature. Heat-inactivated (70'C, 30 min) virus inoculum served as a control for the adequacy of filtering and DNase treatment in eliminating input HIV-1 DNA (6).
PDQ HIV-1 Infectivity Titration. Aliquots (150 1LI) of serial dilutions of virus sample were used to infect 2 x 106 PHAstimulated donor PBMCs in 1.5 ml of growth medium (5) per well of a flat-bottom 24-well plate (Corning). Separate cell samples were counted, harvested, and lysed at 48, 72, and 96 hr. Quantitative PCR and HIV-1 copy-number determination were then performed in duplicate on each lysate. PDQ Susceptibility Testing. The results of a PDQ infectivity titration assay were used to determine the virus dilution and length of culture time employed in a subsequent PDQ susceptibility test. These parameters were chosen so that the yield of HIV-i-specific PCR product for the untreated control infection would fall on the HIV-1 copy-number standard curve before the curve approached its asymptotic maximum, or plateau. PHA-stimulated donor PBMCs were incubated with drug for 4 hr prior to infection. Duplicate wells in a 24-well plate received identical HIV-1 inocula for each drug concentration tested and for the untreated infected controls.
Uninfected controls and drug toxicity controls were included in each experiment. All cultures were harvested and cells were lysed for PCR after either 48 or 72 hr. The entire experiment was repeated without analysis whenever HIV-1 DNA was amplifiable from input HIV-1 DNA controls (i.e., heat-inactivated virus inoculum). Previously characterized isolates were used as assay standards in each experiment (1, 5) .
HIV-1 p24 Antigen-Based Susceptibility Testing. Susceptibility testing based on enzyme-linked immunoassay (DuPont/NEN) of HIV-1 p24 antigen was performed with 7-or 10-day cultures (5) . Virus stocks were used in this assay following infectivity titration by end-point dilution (7) .
Quantitative PCR. Cell pellets were lysed in various volumes oflysis buffer (50 mM KCl/10 mM Tris HCl, pH 8.3/2.5 mM MgCl2/0.5% Nonidet P-40/0.5% Tween 20/0.01% proteinase K) to yield a concentration of 1.2 x 104 cell equivalents/,ul (8) . Uniformity of cell lysate DNA concentrations was confirmed in representative experiments by enhanceAbbreviations: PBMC, peripheral blood mononuclear cell; PDQ, PCR DNA quantitation; RT, reverse transcriptase; HIV-1, human immunodeficiency virus type 1; AZT, 3'-azido-3'-deoxythymidine; ddI, 2',3'-dideoxyinosine; ELOSA, enzyme-linked oligonucleotide solution sandwich hybridization assay; PHA, phytohemagglutinin. *To whom reprint requests should be addressed.
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A conserved primer pair was synthesized according to the HIV-1 LAI (formerly BRU) sequence, GenBank accession no. K02013: 5' primer (sense strand), bases 1889-1908; 3' primer (antisense strand), bases 2211-2192. The primers were used to amplify a 323-base-pair fragment of the HIV-1 pol gene from 1.2 x i05 cell equivalents of lysate by using PCR (GeneAmp, Cetus) under previously described conditions (10) . Following one cycle of 2 min at 940C, 1 min at 450C, and 1 min at 720C, an additional 29 cycles were performed with 1 min at each of those temperatures. Amplifications were repeated if HIV-1 DNA was amplifiable from reagent controls.
HIV-1 pol gene amplification products were specifically detected and quantitated as described (11) . Heat-denatured PCR products were hybridized in a streptavidin-coated microtiter plate well with both biotinylated capture probe and horseradish peroxidase (HRP)-labeled detector probe [ Fig. 1A . The 95% confidence intervals (twice the standard deviation) about the mean amplification yields do not overlap in the portion of the curve between 16 and 1024 copies (Fig. 1A) . The PCR yield plateaus above 1024 copies of preamplification template.
An initial titration of the infectivity of a virus sample was done by PDQ to determine conditions necessary for comparison of relative amounts of HIV-1 DNA synthesized in infected cultures at different drug concentrations. To ensure adequate quantitation of drug effect, the untreated control infection copy number must fall on the pre-plateau portion of the standard curve. An example of a typical PDQ susceptibility test using a primary PBMC coculture supernatant is depicted in Fig. 1B . Results of duplicate amplifications of each of two infections at each drug concentration clustered closely on the standard curve (Fig. 1B) , thereby allowing quantitation of the fractional reduction of mean copy number versus AZT concentration (Fig. 2A) . Representative medianeffect plots testing previously characterized isolates (1, 5) are depicted in Fig. 2 The AZT IC50 values determined by PDQ susceptibility testing were supported by two independent methods: HIV-1 p24 antigen-based susceptibility testing using 7-or 10-day cultures and DNA sequence analysis offour codons of the RT gene implicated in AZT resistance (2) ( Fig. 2 B and D, Fig. 3 B and D) . IC50 values as determined by PDQ or p24 antigen assays were similar to one another for AZT (Table 1 ) and for ddI ( Table   2 ). In both assays, the ddI IC50 values were within a narrow range for isolates from ddI-naive subjects (Table 2) .
PDQ was used to titrate the infectivity of supernatant fluids from 10 unselected HIV-1-positive primary PBMC cocultures to determine the feasibility of directly studying such fluids. PBMC lysates were found to contain an amount of HIV-1 DNA adequate for copy-number comparisons within 72 hr of in vitro infection with 9 of these samples. The 10th supernatant fluid was from a coculture that became HIV-1 p24-positive only after 26 days and was therefore likely to have a low titer of virus. A lysate of PBMCs infected for 72 hr with this sample required 20 more cycles for positivity.
Two of these primary coculture supernatants (349d-3/91 and 100h-3/91), as well as two others, were studied by PDQ susceptibility testing (Fig. 3) . The PDQ IC50 values were consistent with RT gene sequencing results (Table 1) . However, the IC50 values of primary coculture supernatants could [ddIJ uM FIG. 3 . Median-effect plots from PDQ susceptibility tests (three AZT and one ddl) using supernatants from primary PBMC coculture of four clinical isolates. The ACH-2 cell standard curve for each experiment is shown (Insets).
not be confirmed by the previously described p24 susceptibility assay because a larger amount of virus inoculum was needed for that method (5 (Tables 1 and 2 ). The PDQ method offers significant advantages over other antiretroviral-drug resistance assays. Small volumes of low-titer virus-containing supernatants from primary PBMC cocultures, rather than passaged virus, can be used to test drug sensitivity, thus minimizing the selection bias of in vitro culture (14) . Occasional selection of subpopulations of HIV-1 with passage has been seen (15 (Table 2) . In other experiments (data not shown), decreasing the number of PCR cycles from 30 to 26 also decreased the amplification yield from an initial plateau-level copy number to within the range that allows comparisons.
PDQ has allowed quantification of the degree of resistance of all isolates tested, including highly AZT-resistant isolates. Such highly AZT-resistant isolates have been reported to have IC50 values greater than the highest drug concentration tested in other PBMC-based assays (4, 16) . Two theoretical advantages to PDQ susceptibility testing may explain this difference. One advantage may result from the short duration of time needed in culture. AZT-sensitive HIV-1 can be isolated from an in vitro culture after an extended period, despite the presence of AZT (17) . After extended culture, virus isolates with differences in both replication rate and drug susceptibility may appear to have the same IC"0 values.
The early culture end point for PDQ may minimize the risk of artifactually increased IC50 values for rapidly replicating viruses that could result from this phenomenon. A second theoretical advantage ofPDQ testing is specific to agents that inhibit reverse transcription. It is possible that susceptibility tests measuring HIV-1 p24 antigen or RNA production in cultures treated with an RT inhibitor may be less able than PDQ to distinguish a few infected cells making a large amount of these virus products from many infected cells. PDQ may more directly reflect virus spread in such cultures because it directly measures the reverse-transcribed DNA. The heatinactivated virus controls ensure that only newly synthesized HIV-1 DNA is detected in the PDQ tests. Resistance of input HIV-1 DNA to DNase has not been noted.
PDQ susceptibility testing has not yet been limited by the genetic diversity of HIV-1 isolates, although theoretically it is possible that some isolates may not be amplifiable with the primers used here. This single, highly conserved primer pair has amplified HIV-1 DNA from all clinical isolates studied here, as well as from 57 of 59 HIV-1-seropositive individuals' PBMCs in an earlier study (10) . The ability to rapidly test HIV-1 isolates from virtually every subject, with minimal selection pressure from in vitro culture, as well as the theoretical possibility of fewer artifacts than with other methods, suggests that PDQ will be useful for epidemiologic investigation of the pathogenic role of drug-resistant HIV-1.
